Pharmacokinetics and tissue distribution of two novel isomerism anticancer platinum compounds

References

• Dhara S, Lippard SJ. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci USA 2009;106:22199–204.
   PubMed Web of Science ®Google Scholar
• Cleare MJ, Hoeschle JD. Studies on the antitumor activity of group VIII transition metal complexes. Part 1. Platinum II complexes. Bioinorg Chem 1973;2:187–95.
   Google Scholar
• Chen J, Yin JY, Li XP, et al. Association of wnt-inducible signaling pathway protein 1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Clin Lung Cancer 2015;16:298–304.
   PubMed Web of Science ®Google Scholar
• Pokataev I, Tryakin A, Tjulandina A, et al. A phase II nonrandomized study of oxaliplatin/doxorubicin combination therapy in the treatment of recurrent ovarian cancer. Cancer 2014;6:11–16.
   Google Scholar
• Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, lipoplatin. Cancer Ther 2007;5:349–76.
   Google Scholar
• Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002;42:317–25.
   PubMed Web of Science ®Google Scholar
• Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999;99:2451–66.
   PubMed Web of Science ®Google Scholar
• Ho YP, Au-Yeung SCF, To KKW. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003;23:633–55.
   PubMed Web of Science ®Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9–23.
   PubMed Web of Science ®Google Scholar
• Gupta A, Long JB, Chen J, et al. Risk of vascular toxicity with platinum based chemotherapy in elderly patients with bladder cancer. J Urol 2016;195:33–40.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Singh MK, Chauhan AS. Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation. Drug Dev Ind Pharm 2015;41:232–8.
   PubMed Web of Science ®Google Scholar
• Bouma M, Nuijen B, Harms R, et al. Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280. Drug Devel Indus Pharm 2003;29:981–95.
   PubMed Web of Science ®Google Scholar
• Fanelli M, Formica M, Fusi V, et al. New trends in platinum and palladium complexes as antineoplastic agents. Coordin Chem Rev 2016;310:41–79.
   Web of Science ®Google Scholar
• Kurata T, Tamura T, Yamamoto N, et al. Phase I and pharmacokinetic (PK) study of nedaplatin (254-S) in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000;29:69.
   Web of Science ®Google Scholar
• Morrison JG, White P, McDougall S, et al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 2000;24:1–10.
   PubMed Web of Science ®Google Scholar
• Shamsuddin S, Al-Baker S, Siddik ZH, Khokhar AR. Synthesis and antitumor activity of new trans-1R,2R-diaminocyclohexaneplatinum(II) complexes containing disubstituted sulfide groups. Inorg Chim Acta 1996;241:101–4.
   Web of Science ®Google Scholar
• Inoue S, Mizuno S. Effects of a new platinum analog, TRK-710, on human lung cancer cell lines. Lung Cancer 1994;11:94.
   Google Scholar
• Saito T, Manabe Y, Saito H. Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin. Otorhinolaryngol Relat Spec 1995;57:235–55.
   Google Scholar
• Oral AY, Cevatemre B, Sarimahmut M, et al. Anti-growth effect of a novel trans-dichloridobis[2-(2-hydroxyethyl)pyridine]platinum (II) complex via induction of apoptosis on breast cancer cell lines. Bioorgan Med Chem 2015;23:4303–10.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Che CM, Ott I. Caffeine derived platinum(II) N-heterocyclic carbene complexes with multiple anti-cancer activities. J Org Chem 2014;782:37–41.
   Web of Science ®Google Scholar
• Dahm D, Bailly C, Karmazin L, Bellemin-Laponnaz S. Synthesis, structural characterization and in vitro anti-cancer activity of functionalized N-heterocyclic carbene platinum and palladium complexes. J Org Chem 2015;794:115–24.
   Web of Science ®Google Scholar
• Khokhar AR, Salaam A, Zahid HS. Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. J Inorg Biochem 1994;54:39–47.
   PubMed Web of Science ®Google Scholar
• Xu QY, Khokhar AR. Synthesis and characterization of N-methyliminodiacetato trans-R,R-, trans-S,S-, and cis-1,2-diaminocyclohexane platinum (IV) complexes: crystal structure of chloro(trans-R,R-1,2-diaminocyclohexane) (N-methyliminodiacetato)platinum(IV) chloride. J Inorg Biochem 1992;48:217–26.
   PubMed Web of Science ®Google Scholar
• Abele R, Clavel M, Monfardini S, et al. Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol 1987;23:387–9.
   PubMedGoogle Scholar
• Volckova E, Weaver E, Bose RN. Insight into the reactive form of the anticancer agent iproplatin. Eur J Med Chem 2008;43:1081–4.
   PubMed Web of Science ®Google Scholar
• Neidle S, Snook CF, Murrer BA, Barnard CFJ. Bis(acetato)amminedichloro(cyclohexylamine)platinum(IV), an orally active anticancer drug. Acta Crystallogr C 1995;51:822–4.
   PubMedGoogle Scholar
• Carr JL, Tingle MD, Mckeage MJ. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol 2006;57:483–90.
   PubMed Web of Science ®Google Scholar
• Frantisek Z, Jaroslav T, Ales K, et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem 2004;47:761–3.
   PubMed Web of Science ®Google Scholar
• Huang R, Sun Y, Zhang XY, et al. Biological evaluation of a novel herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. Biomed Pharmacother 2015;73:116–22.
   PubMed Web of Science ®Google Scholar
• Luo FR, Wyrick SD, Chaney SG. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 1999;44:19–28.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Fanta PT, Running KL. In vitro phase comparision of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Gynecol Oncol 1998;71:308–12.
   PubMed Web of Science ®Google Scholar
• Liu WP, Jiang J, Xie CY, et al. Synthesis, anticancer activity and toxicity of a water-soluble 4S,5S-derivative of heptaplatin, cis-{Pt(II) [(4S,5S)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]·(3-hydroxyl-cyclobutane-1,1-dicarboxylate)}. J Inorg Biochem 2014;140:126–30.
   PubMed Web of Science ®Google Scholar
• Liu WP, Chen XZ, Ye QS, et al. A novel water-soluble heptaplatin analogue with improved antitumor activity and reduced toxicity. Inorg Chem 2011;50:5324–6.
   PubMed Web of Science ®Google Scholar
• Jiang J, Lou L, Zhu X, et al. Synthesis and anti-tumor activity of two new water–soluble derivatives of heptalatin. Chin J Inorg Chem 2014;30:317–22.
   Web of Science ®Google Scholar
• Su Q, Liu QF, Luo GA, et al. Pharmacokinetic investigation on a novel antitumor platinum compound in rabbit plasma by inductively coupled plasma mass spectrometry after intravenous administration. Drug Devel Indus. Pharm 2008;34:472–7.
   PubMed Web of Science ®Google Scholar
• Su Q, Liu QF, Yu Y, et al. Assay of platinum coordination by high performance liquid chromatography. Chin J New Drug 2007;16:791–3.
   Google Scholar
• Liu QF, Li X, Su Q, et al. Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats. Arch Pharm Res. 2009;32:1621–8.
   PubMed Web of Science ®Google Scholar
• Goodisman J, Hagrman D, Tack KA, Souid AK. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006;57:257–67.
   PubMed Web of Science ®Google Scholar
• Welink J, Pechstein B, Vigh WJF. Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1999;675:107–11.
   Web of Science ®Google Scholar
• Hann S, Stefanka Z, Lenz K, Stingeder G. Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS. Anal Bioanal Chem 2005;381:405–12.
   PubMed Web of Science ®Google Scholar
• Costa AC, Vieira MA, Luna AS, Campos RC. Determination of platinum originated from antitumoral drugs in human urine by atomic absorption spectrometric methods. Talanta 2010;82:1647–53.
   PubMed Web of Science ®Google Scholar
• Ehrsson H, Wallin I. Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection. J Chromatogr B 2003;795:291–4.
   PubMed Web of Science ®Google Scholar
• Guo P, Li SL, Gallo JM. Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:43–52.
   PubMed Web of Science ®Google Scholar
• Huang Z, Timerbaev AR, Keppler BK. Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques. J Chromatogr A 2006;1106:75–9.
   PubMed Web of Science ®Google Scholar
• Khuhawar MY, Arain G. Liquid chromatographic determination of cisplatin as platinum(II) in pharmaceutical preparation, serum and urine samples of cancer patients. Talanta 2005;66:34–9.
   PubMed Web of Science ®Google Scholar
• Vieira FP, Mesquita TL, Lara PCP, et al. ET AAS evaluation of the stability and pH-sensitivity of, pH-sensitive stealth liposomes containing cisplatin in mouse plasma. J Pharm Biomed Anal. 2013;84:135–9.
   PubMed Web of Science ®Google Scholar
• Navolotskii DV, Ivanenko NB, Solovyev ND, et al. Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry. Drug Test Anal 2015;7:737–44.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wen YL, Zhang W, et al. Investigation on pharmacokinetics, tissue distribution and excretion of a novel platinum anticancer agent in rats by inductively coupled plasma mass spectrometry (ICP-MS). Xenobiotica 2014;44:757–62.
   PubMed Web of Science ®Google Scholar
• Raghavan R, Mulligan JA. Low-level (PPB) determination of cisplatin in cleaning validation (rinse water) samples. I. An atomic absorption spectrophotometric method, Drug Dev Ind Pharm 2000;26:423–8.
   PubMed Web of Science ®Google Scholar
• Apostoli P. Elements in environmental and occupational medicine. J Chromatogr B Analyt Technol Biomed Life Sci 2002;778:63–97.
   PubMed Web of Science ®Google Scholar
• Zhang JS, Imai T, Suenaga A, Otagiri M. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C. Int J Pharmaceut 2002;240:23–31.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang YJ, Xu CX, et al. Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS. Biol Trace Elem Res 2012;148:203–8.
   PubMed Web of Science ®Google Scholar
• Meng XJ, Yang B, Gao JY, et al. Simultaneous quantitation of two diastereoisomers of lobaplatin in rat plasma by supercritical fluid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. J Sep Sci 2015;38:3803–9.
   PubMed Web of Science ®Google Scholar
• Júnior ÁDC, Mota LG, Nunan EA, et al. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007;80:659–64.
   PubMed Web of Science ®Google Scholar
• Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004;12:3–12.
   PubMed Web of Science ®Google Scholar
• Maeda M, Tanaka S, Ida H, et al. Antitumor activity and tissue distribution of bis(bilato)-1,2-cyclohexanediammineplatinum(II) complexes in BDF1 mice with murine reticulum cell sarcoma (M5076). Cancer Lett 1993;70:57–64.
   PubMed Web of Science ®Google Scholar
• Sova P, Chladek J, Zak F, et al. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. Int J Pharm 2005;288:123–9.
   PubMed Web of Science ®Google Scholar
• Bates PI, Sharma HL, Murrer BA, McAuliffe CA. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound. Cancer Chemother Pharmacol 1996;39:170–5.
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Maehara Y, Sakaguchi Y, et al. Tissue distribution of cis-diamminedichloroplatinum(II) following intraperitoneal administration to patients with recurrent gastric cancer. Oncol 1993;50:214–17.
   Google Scholar
• Minami T, Tohno Y, Tohno S, et al. Tissue platinum after clinical treatment with cisplatin or carboplatin in tumor-bearing patients. Biol Trace Elem Res 1997;58:77–83.
   PubMed Web of Science ®Google Scholar
• Wondergem J, Strebel FR, Stephens LC, et al. Chronic effect of whole-body hyperthermia combined simultaneously with cis-diamminedichloroplatinum (II) on normal tissue in rat. Int J Hyperthermia 1995;1:37–47.
   Web of Science ®Google Scholar
• Li J, Pant A, Chin CF, et al. In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes. Nanomedicine 2014;10:1465–75.
   PubMed Web of Science ®Google Scholar
• Shimada H, Takahasm K, Ffunakoshi T, Kojima S. Protective effects of dithiocarbamates against toxicity of cis-diamminedichloroplatinum in mice. Biol Pharm Bull 1993;16:368–71.
   PubMed Web of Science ®Google Scholar
• Silva H, Silva ACA, Lemos FO, et al. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes. Anti-cancer Drugs 2013;24:131–40.
   PubMed Web of Science ®Google Scholar
• Staffhorst RWHM, Bornb K, Erkelens CAM, et al. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts. Anti-Cancer Drugs 2008;19:721–7.
   PubMed Web of Science ®Google Scholar
• Eiseman JL, Beumer JH, Rigatti LH, et al. Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews. Cancer Chemother Pharmacol 2015;75:143–52.
   PubMed Web of Science ®Google Scholar
• Sabbioni E, Fortaner S, Manenti S, et al. The metallobiochemistry of ultratrace levels of platinum group elements in the rat. Metallomics 2015;7:267–75.
   PubMed Web of Science ®Google Scholar